Cover Image

A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist

Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) and dual GLP‐1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in patients with type 2 diabetes.1 These effects are driven in part by augmenting glucose‐stimulated insulin release (incretin e...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rolien Bosch (Author), Marcella Petrone (Author), Rosalin Arends (Author), Paolo Vicini (Author), Eric J. G. Sijbrands (Author), Sven Hoefman (Author), Nelleke Snelder (Author)
Format:	Book
Published:	Wiley, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model
by: Rolien Bosch, et al.
Published: (2024)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
by: Kamil Pondel, et al.
Published: (2022)

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
by: Qian Zhao, et al.
Published: (2024)

Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
by: Julianah Ore Abiola, et al.
Published: (2024)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024)

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence
by: Emir M. Muzurović MD, MM, et al.
Published: (2022)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022)

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
by: Thomas Monfeuga, et al.
Published: (2024)

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
by: Nazi Song, et al.
Published: (2022)

Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies
by: Fanjing Kong, et al.
Published: (2023)

Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development
by: Martijn vanNoort, et al.
Published: (2024)

Use of Glucagon-like peptide 2 (GLP-2) analogs in inflammatory bowel disease
by: Dobromiła Osuch, et al.
Published: (2024)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
by: Aaron Novikoff, et al.
Published: (2021)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024)

Danuglipron - an innovate GLP agonist - literature short review
by: Agata Frańczuk, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
by: Stav Brown, et al.
Published: (2024)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
by: Hae Young Lee, et al.
Published: (2024)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
by: Sigrid Jall, et al.
Published: (2017)

Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature
by: Khalid Mohammed Alayed
Published: (2023)

Life scientists improve QSP model quality and impact
by: Katherine Kudrycki, et al.
Published: (2024)

How Do We "Validate" a QSP Model?
by: Daniel C. Kirouac
Published: (2018)

INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024)

Retatrutide - revolutionary recently developed GLP agonist - literature review
by: Patrycja Brzozowska, et al.
Published: (2024)

Quantitative systems pharmacology of the eye: Tools and data for ocular QSP
by: Lars Kuepfer, et al.
Published: (2023)

Electrophilic Agonists Modulate the Transient Receptor Potential Ankyrin-1 Channels Mediated by Insulin and Glucagon-like Peptide-1 Secretion for Glucose Homeostasis
by: Marisa Jadna Silva Frederico, et al.
Published: (2023)

GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
by: Taing MW, et al.
Published: (2014)